Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for ROS1-positive non-small-cell lung cancer, drawn from the whole corpus: 17 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial compares the ROS1 inhibitors; choice rests on single-arm response rates and side-effect profiles.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dizziness, weight gain and paraesthesia from TRK inhibition limit the current brain-penetrant drugs.
Resistance through MET, KRAS and other bypass routes has no approved targeted option.
Nothing recorded yet.
Nothing recorded yet.
Background: On-target resistance mutations (gatekeeper, solvent-front, compound). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Repotrectinib produced responses in 79 percent of ROS1 inhibitor-naive patients (median progression-free survival 35.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.